63,800 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Purchased by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System acquired a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 63,800 shares of the medical research company’s stock, valued at approximately $1,032,000. Louisiana State Employees Retirement System owned 0.05% of NeoGenomics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Redwood Investments LLC acquired a new stake in shares of NeoGenomics in the fourth quarter valued at approximately $2,399,000. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of NeoGenomics in the fourth quarter valued at approximately $456,000. Legato Capital Management LLC acquired a new stake in shares of NeoGenomics in the fourth quarter valued at approximately $401,000. Moody National Bank Trust Division increased its stake in shares of NeoGenomics by 22.3% in the fourth quarter. Moody National Bank Trust Division now owns 34,390 shares of the medical research company’s stock valued at $556,000 after purchasing an additional 6,281 shares during the period. Finally, Bullseye Asset Management LLC increased its stake in shares of NeoGenomics by 19.6% in the third quarter. Bullseye Asset Management LLC now owns 163,792 shares of the medical research company’s stock valued at $2,015,000 after purchasing an additional 26,819 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insider Buying and Selling

In related news, General Counsel Alicia C. Olivo sold 2,587 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.96, for a total value of $38,701.52. Following the completion of the transaction, the general counsel now owns 34,866 shares of the company’s stock, valued at approximately $521,595.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.30% of the company’s stock.

NeoGenomics Trading Down 0.9 %

Shares of NASDAQ:NEO opened at $14.03 on Thursday. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -20.04 and a beta of 1.10. NeoGenomics, Inc. has a 1-year low of $11.03 and a 1-year high of $21.22. The company has a debt-to-equity ratio of 0.57, a quick ratio of 5.95 and a current ratio of 6.20. The company has a 50 day moving average price of $15.06 and a 200 day moving average price of $15.89.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. NeoGenomics had a negative net margin of 14.87% and a negative return on equity of 4.13%. The firm had revenue of $155.55 million during the quarter, compared to analysts’ expectations of $152.90 million. On average, research analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NEO. William Blair restated an “outperform” rating on shares of NeoGenomics in a research note on Wednesday, February 21st. Needham & Company LLC increased their price objective on shares of NeoGenomics from $21.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, February 21st. TD Cowen decreased their price objective on shares of NeoGenomics from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Friday, December 29th. BTIG Research decreased their price objective on shares of NeoGenomics from $25.00 to $21.00 and set a “buy” rating for the company in a report on Friday, December 29th. Finally, The Goldman Sachs Group increased their price objective on shares of NeoGenomics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, NeoGenomics currently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.